These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35112455)

  • 1. Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.
    Waijer SW; Provenzano M; Mulder S; Rossing P; Persson F; Perkovic V; Heerspink HJL
    Diabetes Obes Metab; 2022 Jun; 24(6):983-990. PubMed ID: 35112455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study.
    Fung CS; Wan EY; Chan AK; Lam CL
    BMC Nephrol; 2017 Feb; 18(1):47. PubMed ID: 28152985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Vaduganathan M; Pareek M; Kristensen AMD; Biering-Sørensen T; Byrne C; Almarzooq Z; Olesen TB; Olsen MH; Bhatt DL
    Eur J Heart Fail; 2021 Mar; 23(3):384-392. PubMed ID: 33448580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
    Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
    Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stronger Association of Albuminuria with the Risk of Vascular Complications than Estimated Glomerular Filtration Rate in Type 2 Diabetes.
    Hong X; Huang L; Zhang Y; Shen X; Weng S; Zeng F; Zhao F; Yan S
    Kidney Blood Press Res; 2021; 46(5):550-562. PubMed ID: 34428770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
    Rossing P; Bain SC; Bosch-Traberg H; Sokareva E; Heerspink HJL; Rasmussen S; Mellbin LG
    Cardiovasc Diabetol; 2023 Aug; 22(1):220. PubMed ID: 37620807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults.
    Kühn A; van der Giet M; Kuhlmann MK; Martus P; Mielke N; Ebert N; Schaeffner ES
    Am J Kidney Dis; 2021 Mar; 77(3):386-396.e1. PubMed ID: 33197533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can both normal and mildly abnormal albuminuria and glomerular filtration rate be a danger signal for diabetic peripheral neuropathy in type 2 diabetes mellitus?
    Zhang Y; Jiang Y; Shen X; Yan S
    Neurol Sci; 2017 Aug; 38(8):1381-1390. PubMed ID: 28478497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial.
    Turbay-Caballero V; Ricardo AC; Chen J; Missikpode C; Lash JP; Aroca-Martinez G; Musso CG
    Kidney Med; 2024 Jul; 6(7):100845. PubMed ID: 38966681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and validation of the cut-off values of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio for diabetic kidney disease: A multi-center, prospective cohort study.
    Gao Z; Zhu Y; Sun X; Zhu H; Jiang W; Sun M; Wang J; Liu L; Zheng H; Qin Y; Zhang S; Yang Y; Xu J; Yang J; Shan C; Chang B
    Front Endocrinol (Lausanne); 2022; 13():1064665. PubMed ID: 36578951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
    Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
    Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
    Mosenzon O; Bain SC; Heerspink HJL; Idorn T; Mann JFE; Persson F; Pratley RE; Rasmussen S; Rossing P; von Scholten BJ; Raz I;
    Diabetes Obes Metab; 2020 Nov; 22(11):2077-2088. PubMed ID: 32618386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.